Schizotypal personality disorder — assessment and stepped management (MEQ)

(i) Working diagnosis and differentials. Working diagnosis: schizotypal personality disorder (lifelong social deficits, ideas of reference with residual doubt, eccentric style, lack of close friends, excessive social anxiety with paranoid tone) with comorbid depressive symptoms and cannabis use, plus recent functional decline that raises clinical high-risk concern. Differentials: schizophrenia/other psychotic disorder (against: residual insight, no sustained frank delusions/hallucinations); clinical high risk / attenuated psychosis (for: 4-month withdrawal and job loss — document UHR features carefully); ASD (need developmental social-communication history); schizoid PD (would lack cognitive-perceptual oddness); paranoid PD (distrust without broader oddness); substance-induced perceptual anomalies; OCD with poor insight. Organic exclusion if atypical/late features emerge.[1][2][4]

(ii) Assessment priorities. Longitudinal history and collateral; full MSE focusing on conviction versus doubt of referential ideas, perception, thought form, affect, insight; depression severity and suicide risk (isolation + job loss + cannabis); self-neglect and exploitation vulnerability; capacity decision-specific; cannabis pattern (amount, potency, motives); developmental history for ASD; family history of psychosis; baseline investigations before any psychotropic (UDS, metabolic/TSH as indicated). Conversion monitoring: rising conviction, hallucinations, hygiene collapse, further functional drop.[1][4][5]

(iii) Medium-term psychosocial plan. Alliance-first engagement with transparent goals (mood, sleep, work, cannabis). Supportive psychotherapy and CBT adaptations for referential thinking and social anxiety without aggressive early belief confrontation. Social skills and vocational support. Motivational work on cannabis reduction. Psychoeducation that STPD is a recognised pattern and that many people remain non-psychotic with support. Consistent named clinician; family involvement if accepted. Schema-informed or structured PD approaches if broader personality pathology and service access allow.[1][2]

(iv) Pharmacotherapy principles. No drug treats STPD as a whole. Treat comorbidity first. Example: if major depressive episode is confirmed, sertraline 50 mg orally daily, early review for activation/adherence, titrate toward 50–150 mg as tolerated, limited dispensing if overdose risk, and review mood/suicidality. A time-limited low-dose second-generation antipsychotic may be considered only for severe distressing cognitive-perceptual symptoms with written target, baseline metabolic/ECG risk assessment as indicated, monitoring, and stop/review date — evidence certainty is limited (Jakobsen/Kirchner). Do not start chronic polypharmacy for eccentricity alone.[2][3]

(v) Disposition and early psychosis interface. Prefer outpatient with close follow-up given residual insight and absence of frank psychosis, unless suicide risk, severe self-neglect, or emerging psychosis requires more intensive care. Involve early psychosis / UHR services if attenuated positives plus functional decline meet local referral thresholds or conviction escalates. Reassess urgently if clear voices, fixed delusions, or marked collapse appear — switch to psychosis pathway.[4][5]